About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 2NCT00710970

Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment

The major objective of this two-stage phase II study is to determine whether tamoxifen is deserving of further study in metastatic bladder cancer. Tamoxifen is expected to function as a cytostatic (an...

Lead sponsor: Seth Lerner•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Seth Lerner

Collaborators

AstraZeneca
Cytogen Corporation

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients previously diagnosed with bladder cancer who have already received 1-2 systemic therapy regimens (chemotherapy or biological therapy or both) but including at least one chemotherapy regimen.
•Patients who have had the cancer spread to other parts of the body.
•Patients must have adequate liver function.

Exclusion Criteria

•Patients who have uncontrolled nervous system metastasis
•Patients who are pregnant
•Patients who have had systemic therapies within the past 4 weeks
•Patients who plan to have major surgery within 2 weeks
•Patients who have Grade III/IV heart problems
•Patients who have severe and/or uncontrolled medical disease.
•Patients who might be at high risk for deep vein thrombosis

Related studies

RECRUITINGPhase 1

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

NCT04389632 · Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, and more

Early vs Delayed Intravesical Blad-Care During BCG Therapy

NCT07495072 · Urinary Bladder Neoplasms, BCG-Induced Cystitis

RECRUITINGPhase 1/2

A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)

NCT07222488 · Bladder Cancer, Urinary Bladder Neoplasms

RECRUITINGPhase 1

FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

NCT05614739 · Urinary Bladder Neoplasms, Neoplasm Metastasis, and more

RECRUITINGPhase 3

Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

NCT06441110 · Urinary Bladder Neoplasms, BCG Vaccine, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 24, 2022Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment28

Start dateJan 2007

Last updatedJan 24, 2022

Condition

Urinary Bladder Neoplasms

Locations shown

Baylor College Of Medicine

Houston, Texas

San Camillo and Forlanini Hospitals

Rome

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 24, 2022Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions